175 related articles for article (PubMed ID: 17613663)
1. Magnetic poly epsilon-caprolactone nanoparticles containing Fe3O4 and gemcitabine enhance anti-tumor effect in pancreatic cancer xenograft mouse model.
Gang J; Park SB; Hyung W; Choi EH; Wen J; Kim HS; Shul YG; Haam S; Song SY
J Drug Target; 2007 Jul; 15(6):445-53. PubMed ID: 17613663
[TBL] [Abstract][Full Text] [Related]
2. Temperature-sensitive magnetic drug carriers for concurrent gemcitabine chemohyperthermia.
Kim DH; Guo Y; Zhang Z; Procissi D; Nicolai J; Omary RA; Larson AC
Adv Healthc Mater; 2014 May; 3(5):714-24. PubMed ID: 24574255
[TBL] [Abstract][Full Text] [Related]
3. Preparation of poly epsilon-caprolactone nanoparticles containing magnetite for magnetic drug carrier.
Yang J; Park SB; Yoon HG; Huh YM; Haam S
Int J Pharm; 2006 Nov; 324(2):185-90. PubMed ID: 16872766
[TBL] [Abstract][Full Text] [Related]
4. Polyisoprenoyl gemcitabine conjugates self assemble as nanoparticles, useful for cancer therapy.
Maksimenko A; Mougin J; Mura S; Sliwinski E; Lepeltier E; Bourgaux C; Lepêtre S; Zouhiri F; Desmaële D; Couvreur P
Cancer Lett; 2013 Jul; 334(2):346-53. PubMed ID: 22935679
[TBL] [Abstract][Full Text] [Related]
5. Long-circulatory nanoparticles for gemcitabine delivery: Development and investigation of pharmacokinetics and in-vivo anticancer efficacy.
Khare V; Singh A; Mahajan G; Alam N; Kour S; Gupta M; Kumar A; Singh G; Singh SK; Saxena AK; Mondhe DM; Gupta PN
Eur J Pharm Sci; 2016 Sep; 92():183-93. PubMed ID: 27404580
[TBL] [Abstract][Full Text] [Related]
6. Combining Gemcitabine-Loaded Macrophage-like Nanoparticles and Erlotinib for Pancreatic Cancer Therapy.
Cai H; Wang R; Guo X; Song M; Yan F; Ji B; Liu Y
Mol Pharm; 2021 Jul; 18(7):2495-2506. PubMed ID: 34078087
[TBL] [Abstract][Full Text] [Related]
7. In vitro and in vivo anti-tumor activities of a gemcitabine derivative carried by nanoparticles.
Sloat BR; Sandoval MA; Li D; Chung WG; Lansakara-P DS; Proteau PJ; Kiguchi K; DiGiovanni J; Cui Z
Int J Pharm; 2011 May; 409(1-2):278-88. PubMed ID: 21371545
[TBL] [Abstract][Full Text] [Related]
8. Site specific/targeted delivery of gemcitabine through anisamide anchored chitosan/poly ethylene glycol nanoparticles: an improved understanding of lung cancer therapeutic intervention.
Garg NK; Dwivedi P; Campbell C; Tyagi RK
Eur J Pharm Sci; 2012 Dec; 47(5):1006-14. PubMed ID: 23041219
[TBL] [Abstract][Full Text] [Related]
9. Gemcitabine-based therapy for pancreatic cancer using the squalenoyl nucleoside monophosphate nanoassemblies.
Maksimenko A; Caron J; Mougin J; Desmaële D; Couvreur P
Int J Pharm; 2015 Mar; 482(1-2):38-46. PubMed ID: 25448549
[TBL] [Abstract][Full Text] [Related]
10. Preparation of intravenous injection nanoformulation of VESylated gemcitabine by co-assembly with TPGS and its anti-tumor activity in pancreatic tumor-bearing mice.
Xu Y; Meng H; Du F; Lu W; Liu S; Huang J; Yu J
Int J Pharm; 2015 Nov; 495(2):792-7. PubMed ID: 26410754
[TBL] [Abstract][Full Text] [Related]
11. EGFR-targeted gelatin nanoparticles for systemic administration of gemcitabine in an orthotopic pancreatic cancer model.
Singh A; Xu J; Mattheolabakis G; Amiji M
Nanomedicine; 2016 Apr; 12(3):589-600. PubMed ID: 26656632
[TBL] [Abstract][Full Text] [Related]
12. [Effects of magnetic gemcitabine stealth nano-liposomes on the characteristics of breast cancer cell line MCF-7].
Tong Q; Shu XG; Lu XM; Li WY; Tao KX; Chen DD; Wang GB
Yao Xue Xue Bao; 2009 Feb; 44(2):181-7. PubMed ID: 19408690
[TBL] [Abstract][Full Text] [Related]
13. pH-Sensitive Nanodrug Carriers for Codelivery of ERK Inhibitor and Gemcitabine Enhance the Inhibition of Tumor Growth in Pancreatic Cancer.
Ray P; Dutta D; Haque I; Nair G; Mohammed J; Parmer M; Kale N; Orr M; Jain P; Banerjee S; Reindl KM; Mallik S; Kambhampati S; Banerjee SK; Quadir M
Mol Pharm; 2021 Jan; 18(1):87-100. PubMed ID: 33231464
[TBL] [Abstract][Full Text] [Related]
14. Squalenoyl gemcitabine nanomedicine overcomes the low efficacy of gemcitabine therapy in pancreatic cancer.
Réjiba S; Reddy LH; Bigand C; Parmentier C; Couvreur P; Hajri A
Nanomedicine; 2011 Dec; 7(6):841-9. PubMed ID: 21419876
[TBL] [Abstract][Full Text] [Related]
15. Magnetic functionalised carbon nanotubes as drug vehicles for cancer lymph node metastasis treatment.
Yang F; Jin C; Yang D; Jiang Y; Li J; Di Y; Hu J; Wang C; Ni Q; Fu D
Eur J Cancer; 2011 Aug; 47(12):1873-82. PubMed ID: 21493061
[TBL] [Abstract][Full Text] [Related]
16. Efficient overcoming of drug resistance to anticancer nucleoside analogs by nanodelivery of active phosphorylated drugs.
Galmarini CM; Warren G; Senanayake MT; Vinogradov SV
Int J Pharm; 2010 Aug; 395(1-2):281-9. PubMed ID: 20580798
[TBL] [Abstract][Full Text] [Related]
17. Distribution of Gemcitabine Is Nearly Homogenous in Two Orthotopic Murine Models of Pancreatic Cancer.
Kramer RM; Russell J; Humm JL
Cancer Biother Radiopharm; 2015 Sep; 30(7):299-304. PubMed ID: 26203552
[TBL] [Abstract][Full Text] [Related]
18. Diels Alder-mediated release of gemcitabine from hybrid nanoparticles for enhanced pancreatic cancer therapy.
Oluwasanmi A; Al-Shakarchi W; Manzur A; Aldebasi MH; Elsini RS; Albusair MK; Haxton KJ; Curtis ADM; Hoskins C
J Control Release; 2017 Nov; 266():355-364. PubMed ID: 28943195
[TBL] [Abstract][Full Text] [Related]
19. Chemosensitization and inhibition of pancreatic cancer stem cell proliferation by overexpression of microRNA-205.
Chaudhary AK; Mondal G; Kumar V; Kattel K; Mahato RI
Cancer Lett; 2017 Aug; 402():1-8. PubMed ID: 28536008
[TBL] [Abstract][Full Text] [Related]
20. A new liposomal formulation of Gemcitabine is active in an orthotopic mouse model of pancreatic cancer accessible to bioluminescence imaging.
Bornmann C; Graeser R; Esser N; Ziroli V; Jantscheff P; Keck T; Unger C; Hopt UT; Adam U; Schaechtele C; Massing U; von Dobschuetz E
Cancer Chemother Pharmacol; 2008 Mar; 61(3):395-405. PubMed ID: 17554540
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
